Stem Cell Therapy for Parkinson’s Disease
Parkinson’s disease is a progressive condition caused by the loss of brain nerve cells responsible for dopamine production which is crucial for coordination of movement. The causes of decline of dopamine production remains unknown but the scientists link the development of Parkinson’s disease to different factors, most often to environmental and genetic factors. In addition to the available treatments of Parkinson’s disease, the patients may also benefit from the stem cell therapy which is both affordable and safe at the Integra Medical Center just across the border in Mexico. Over 50 patients from Mexico, the United States and Canada have received the stem cell therapy at the Integra Medical Center.
Dr. Omar Gonzales, director and founder of the Integra Medical Center uses stem cells therapy for treatment of Parkinson’s disease and claims that the patients who received the stem cell therapy experienced drastic improvement. After the treatment, the patients are reported to experience improvement in balance and coordination for 80 percent, decrease of stiffness and rigidity for 70 percent, improved mental clarity for 50 percent and mood improvement for 80 percent, having less tremor for 60 percent and reduced dependency on other people for 90 percent. In addition, Dr. Gonzales says, his patients even experience reversal of the symptoms of Parkinson’s disease after the treatment. Stem cells used in Dr. Gonzales’ therapy are prepared and kept at the Center’s laboratory.
Dr. Gonzales’ explains that the results of his stem cell therapy have three levels: slowing down the disease’s progression, inhibiting the disease’s progression and reverse of the disease’s symptoms. The last level is reported to be achieved in over 80 percent of all patients. The outcome of the Dr. Gonzales’ therapy greatly depends on several factors in first place on the age of the patient, time of occurrence of the symptoms and level of progression of the disease at the start of the treatment.

















Subscribe to the comments for this post